Literature DB >> 21691114

Targeting nuclear bile acid receptors for liver disease.

Michael Trauner1, Anna Baghdasaryan, Thierry Claudel, Peter Fickert, Emina Halilbasic, Tarek Moustafa, Gernot Zollner.   

Abstract

Bile acids (BAs) are able to activate a range of dedicated nuclear receptors (NRs) which play a key role in the transcriptional control of critical steps of a wide range of hepatic functions ranging from BA homeostasis and bile formation, phase I/II metabolism of endo- and xenobiotics such as BAs and drugs, respectively, to hepatic lipids and glucose metabolism. Apart from these metabolic roles, BA-activated nuclear receptors also play a key role in the control of hepatic inflammation, fibrogenesis, replication of hepatitis B and C virus, liver regeneration and carcinogenesis. As such, several physiological and pathophysiological effects of BAs can now be explained through activation of regulatory NR networks. Moreover, BA-activated NRs are key for understanding the pathogenesis of several liver diseases and represent attractive drug targets. This article will provide a brief overview on the role of BA-activated NRs in cholestatic and fatty liver disease.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691114     DOI: 10.1159/000324141

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  8 in total

Review 1.  Liver - guardian, modifier and target of sepsis.

Authors:  Pavel Strnad; Frank Tacke; Alexander Koch; Christian Trautwein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

Review 2.  [Shock liver and cholestatic liver in critically ill patients].

Authors:  A Drolz; T Horvatits; K Roedl; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-27       Impact factor: 0.840

Review 3.  Novel insight into mechanisms of cholestatic liver injury.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

Review 4.  Beyond intestinal soap--bile acids in metabolic control.

Authors:  Folkert Kuipers; Vincent W Bloks; Albert K Groen
Journal:  Nat Rev Endocrinol       Date:  2014-05-13       Impact factor: 43.330

5.  Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.

Authors:  Rajeshwar P Mookerjee; Gautam Mehta; Vairappan Balasubramaniyan; Fatma El Zahraa Mohamed; Nathan Davies; Vikram Sharma; Yasuko Iwakiri; Rajiv Jalan
Journal:  J Hepatol       Date:  2014-08-23       Impact factor: 25.083

Review 6.  Clinical application of transcriptional activators of bile salt transporters.

Authors:  Anna Baghdasaryan; Peter Chiba; Michael Trauner
Journal:  Mol Aspects Med       Date:  2013-12-12

Review 7.  Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?

Authors:  Anna Czarnecka; Krzysztof Milewski; Magdalena Zielińska
Journal:  Neurochem Res       Date:  2016-11-25       Impact factor: 3.996

8.  Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B.

Authors:  Kaitao Zhao; Shuhui Liu; Yingshan Chen; Yongxuan Yao; Ming Zhou; Yifei Yuan; Yun Wang; Rongjuan Pei; Jizheng Chen; Xue Hu; Yuan Zhou; He Zhao; Mengji Lu; Chunchen Wu; Xinwen Chen
Journal:  Emerg Microbes Infect       Date:  2018-11-21       Impact factor: 7.163

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.